Overview

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Status:
Recruiting
Trial end date:
2028-10-31
Target enrollment:
Participant gender:
Summary
This is a Multi-center, Open-label, Single-arm Phase II Study to Evaluate the Efficacy and Safety of HL-085 in the treatment of Adult Participants with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas(PN)
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Kechow Pharma, Inc.